Kin Man Au, Ph.D.

Kin Man Au, Ph.D., received his Ph.D. in chemistry from the University of Sheffield in 2013. Afterward, he completed a postdoctoral fellowship at the University of North Carolina at Chapel Hill and subsequently accepted a faculty position at UT Southwestern Medical Center. His research interests include cancer, drug delivery, polymer chemistry, biomedical imaging, photothermal therapy, radiotherapy & nuclear medicine, and cancer immunotherapy.

• Autoimmune diseases
• Biomaterials
• Biomedical imaging
• Cancer
• Cancer immunotherapy
• Chemoradiotherapy adoptive cell therapy
• Chemotherapy
• Drug delivery
• In vivo animal model
• Low-cost point-of-care diagnostic test
• Photothermal therapy
• Polymer chemistry
• Radiotherapy and nuclear medicine

An injectable subcutaneous colon-specific immune niche for the treatment of ulcerative colitis

Au KM, Wilson JE, Ting JP, Wang AZ Nature Biomedical Engineering 2023

Immune Checkpoint Ligand Bioengineered Schwann Cells as Antigen-Specific Therapy for Experimental Autoimmune Encephalomyelitis

Au KM, Tisch R, Wang AZ Advanced Materials 2022 Feb 34

In Vivo Bioengineering of Beta Cells with Immune Checkpoint Ligand as a Treatment for Early-Onset Type 1 Diabetes Mellitus

Au KM, Tisch R, Wang AZ ACS Nano 2021 Dec 15 19990-20002

Immune Checkpoint-Bioengineered Beta Cell Vaccine Reverses Early-Onset Type 1 Diabetes

Au KM, Medik Y, Ke Q, Tisch R, Wang AZ Advanced Materials 2021 Jun 33

Co-delivery of etoposide and cisplatin in dual-drug loaded nanoparticles synergistically improves chemoradiotherapy in non-small cell lung cancer models

Zhang M, Hagan CT, Foley H, Tian X, Yang F, Au KM, Mi Y, Medik Y, Roche K, Wagner K, Rodgers Z, Min Y, Wang AZ Acta Biomaterialia 2021 Apr 124 327-335

Trispecific natural killer cell nanoengagers for targeted chemoimmunotherapy

Au KM, Par SI, Wa AZ Science Advances 2020 Jul 6

Pretargeted delivery of PI3K/mTOR small-molecule inhibitor–loaded nanoparticles for treatment of non-Hodgkin’s lymphoma

Au KM, Wang AZ, Park SI Science Advances 2020 Apr 6

High-Performance Concurrent Chemo-Immuno-Radiotherapy for the Treatment of Hematologic Cancer through Selective High-Affinity Ligand Antibody Mimic-Functionalized Doxorubicin-Encapsulated Nanoparticles

Au KM, Balhorn R, Balhorn MC, Park SI, Wang AZ ACS Central Science 2019 Jan 5 122-144

Nanoparticle co-delivery of wortmannin and cisplatin synergistically enhances chemoradiotherapy and reverses platinum resistance in ovarian cancer models

Zhang M, Hagan CT, Min Y, Foley H, Tian X, Yang F, Mi Y, Au KM, Medik Y, Roche K, Wagner K, Rodgers Z, Wang AZ Biomaterials 2018 Jul 169 1-10

Bespoke Pretargeted Nanoradioimmunotherapy for the Treatment of Non-Hodgkin Lymphoma

Au KM, Tripathy A, Lin CP, Wagner K, Hong S, Wang AZ, Park SI ACS Nano 2018 Feb 12 1544-1563

• Raleigh Award for Excellence in Biology Research, Department of Radiation Oncology, University of North Carolina (UNC)-Chapel Hill, NC
  (2020)
• Best Poster Award, UK Macro Group 3rd International Polymer Chemistry Conference
  (2012)
• The Wharton Prize, University of Sheffield (UK)
  (2004)

• American Chemical Society, Member (2007)